

## Suvorexant Formulation

Version            Revision Date:            SDS Number:            Date of last issue: 12/06/2025  
7.0                05/09/2026              21525-00028            Date of first issue: 10/14/2014

---

### SECTION 1. IDENTIFICATION

Product name                            : Suvorexant Formulation  
Other means of identification        : No data available

#### Manufacturer or supplier's details

Company name of supplier        : Merck & Co., Inc  
Address                                 : 126 E. Lincoln Avenue  
    : Rahway, New Jersey U.S.A. 07065  
Telephone                             : 908-740-4000  
Emergency telephone                : 1-908-423-6000  
E-mail address                        : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use                    : Pharmaceutical  
Restrictions on use                  : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Specific target organ toxicity       : Category 2 (Central nervous system)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms                    :



Signal Word                            : Warning

Hazard Statements                    : H373 May cause damage to organs (Central nervous system)  
through prolonged or repeated exposure if swallowed.

Precautionary Statements         : **Prevention:**  
P260 Do not breathe dust.  
**Response:**  
P314 Get medical attention if you feel unwell.  
**Disposal:**  
P501 Dispose of contents and container to an approved waste  
disposal plant.

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	Common Name/Synonym	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Suvorexant	No data available	1030377-33-3*	>= 3 - <= 7	TSC
Magnesium stearate	Octadecanoic acid, magnesium salt (2:1)	557-04-0*	>= 0.5 - <= 1.5	TSC

\* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.  
Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
7.0	05/09/2026	21525-00028	Date of first issue: 10/14/2014

---

- potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
- 

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.
-

## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Suvorexant	1030377-33-3	TWA	14 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	140 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Inhalable)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (Respirable)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (inhalable dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWAEV (respirable aerosol fraction)	3 mg/m <sup>3</sup>	CA QC OEL
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

---

containment devices).  
Minimize open handling.

### Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Color : No data available
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable



## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
7.0	05/09/2026	21525-00028	Date of first issue: 10/14/2014

---

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Suvorexant:

Acute oral toxicity	:	LD50 (Rat): > 1,200 mg/kg LD50 (Dog): > 1,125 mg/kg LDLo (Mouse): 2,000 mg/kg
---------------------	---	---

##### Magnesium stearate:

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Suvorexant:

Species	:	Rabbit
Result	:	No skin irritation

##### Magnesium stearate:

Species	:	Rabbit
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

---

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Suvorexant:

Species : Bovine cornea  
Result : Mild eye irritation  
Method : Bovine cornea (BCOP)

##### Magnesium stearate:

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

#### Respiratory sensitization

Not classified based on available information.

#### Components:

##### Suvorexant:

Test Type : Local lymph node assay (LLNA)  
Species : Mouse  
Assessment : Does not cause skin sensitization.  
Result : negative

##### Magnesium stearate:

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Suvorexant:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: Alkaline elution assay  
Test system: rat hepatocytes  
Result: negative

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

---

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative

: Test Type: Micronucleus test  
Species: Mouse  
Result: negative

Test Type: Micronucleus test  
Species: Rat  
Result: negative

### Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

### Components:

#### Suvorexant:

Species : Mouse  
Application Route : Oral  
Exposure time : 6 month(s)  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Suvorexant:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity Parent: NOAEL: >= 325 mg/kg body weight  
Result: negative

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

---

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rabbit, female  
Application Route: Oral  
Developmental Toxicity: NOAEL: 150 mg/kg body weight  
Result: negative

Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 80 mg/kg body weight  
Result: negative

### **Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### **STOT-single exposure**

Not classified based on available information.

### **Components:**

#### **Suvorexant:**

Remarks : Based on human experience.

### **STOT-repeated exposure**

May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

### **Components:**

#### **Suvorexant:**

Routes of exposure : Ingestion  
Target Organs : Central nervous system  
Assessment : May cause damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

---

### Repeated dose toxicity

#### Components:

##### **Suvorexant:**

Species : Rat  
NOAEL : 325 mg/kg  
LOAEL : 1,200 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Blood, Pancreas

Species : Dog  
NOAEL : 50 mg/kg  
LOAEL : 125 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Blood, Liver, Central nervous system

Species : Rat  
NOAEL : 75 mg/kg  
LOAEL : 300 mg/kg  
Application Route : Oral  
Exposure time : 180 d  
Target Organs : Pancreas, Blood, Stomach

Species : Dog  
NOAEL : 50 mg/kg  
LOAEL : 125 mg/kg  
Application Route : Oral  
Exposure time : 270 d  
Target Organs : Blood

Species : Rat  
NOAEL : 40 mg/kg  
LOAEL : 80 mg/kg  
Application Route : Oral  
Exposure time : 18 Months  
Target Organs : Eye, Central nervous system

##### **Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### Aspiration toxicity

Not classified based on available information.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

### Experience with human exposure

#### Components:

##### **Suvorexant:**

Ingestion : Symptoms: Drowsiness, Headache, abnormal dreams, Fatigue, Dizziness, dry mouth, Nausea, liver function change, upper respiratory tract infection, urinary tract infection, Cough, Diarrhea, Palpitation, tachycardia

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### **Suvorexant:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Mysidopsis bahia (opossum shrimp)): 0.56 mg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 5 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.5 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.14 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.5 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

##### **Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

	Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EL50 ( <i>Daphnia magna</i> (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	: EL50 ( <i>Pseudokirchneriella subcapitata</i> (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility.
	NOELR ( <i>Pseudokirchneriella subcapitata</i> (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC10 ( <i>Pseudomonas putida</i> ): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

### Persistence and degradability

#### Components:

##### **Suvorexant:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 81 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	: Hydrolysis: < 10 %(5 d) Method: OECD Test Guideline 111

##### **Magnesium stearate:**

Biodegradability	: Result: Not biodegradable Remarks: Based on data from similar materials
------------------	--

### Bioaccumulative potential

#### Components:

##### **Suvorexant:**

Bioaccumulation	: Species: <i>Lepomis macrochirus</i> (Bluegill sunfish) Bioconcentration factor (BCF): 358
-----------------	--

## Suvorexant Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 21525-00028      Date of last issue: 12/06/2025  
Date of first issue: 10/14/2014

---

Method: OECD Test Guideline 305  
Partition coefficient: n-octanol/water : log Pow: 4.04

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil**

No data available

**Other adverse effects**

No data available

**Endocrine disrupting properties**

No data available

---

### SECTION 13. DISPOSAL CONSIDERATIONS

**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

### SECTION 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation**

**TDG**

Not regulated as a dangerous good

**Special precautions for user**

Not applicable

---

### SECTION 15. REGULATORY INFORMATION

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

---

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
7.0	05/09/2026	21525-00028	Date of first issue: 10/14/2014

CA. DSL : not determined

CN IECSC : not determined

### Canadian lists

No substances are subject to CEPA Section 84 Ministerial Conditions.

## SECTION 16. OTHER INFORMATION

### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWAEV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2025
7.0	05/09/2026	21525-00028	Date of first issue: 10/14/2014

---

Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/09/2026  
Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8